JOYO PHARMA
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.
JOYO PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2017-01-01
Address:
Guangzhou, Guangdong, China
Country:
China
Status:
Active
Total Funding:
300 M CNY
Investors List
Sequoia Capital China
Sequoia Capital China investment in Series B - Joyo Pharma
SDIC Venture Capital
SDIC Venture Capital investment in Series B - Joyo Pharma
More informations about "Joyo Pharma"
Joyo Pharma - Crunchbase Company Profile & Funding
Joyo Pharma closed its last funding round on Jun 7, 2023 from a Series C round. Who are Joyo Pharma 's competitors? Alternatives and possible competitors โฆSee details»
Joyo Pharma - Funding, Financials, Valuation & Investors
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.See details»
Joyo Pharma 2025 Company Profile: Valuation, โฆ
Joyo Pharma General Information Description. Developer of new drugs designed for treatment of tumor, autoimmunity, metabolism and infectious diseases. The company's drugs take translational and clinical medicine as the core and โฆSee details»
JOYO PHARMA complete pre-C round of financing
Jun 8, 2023 JOYO PHARMA follows the philosophy of โIn China, for Globalโ and focuses on tumors, autoimmunity, metabolism and infectious diseases. JOYO PHARMA has a number of innovative drug projects, and a number of clinical โฆSee details»
Guangzhou JOYO Pharma Company - PitchBook
Information on valuation, funding, acquisitions, investors, and executives for Guangzhou JOYO Pharma Company. Use the PitchBook Platform to explore the full profile.See details»
Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.
Mar 8, 2025 Guangzhou JOYO Pharma Co., Ltd. is a business entity based in Guangzhou, China, which specializes in creating diagnostic products for pathological purposes. ... The statistics for drugs in the Pipeline is the current โฆSee details»
Guangzhou Joyo Pharma | ApexOnco - Clinical Trials news and โฆ
Dec 18, 2023 The young companyโs eighth licensing deal brings in two RAS-targeting projects from Joyo. Read more. Trial results. 18 December 2023. ... Read more. Subscribe to โฆSee details»
Joyo Pharma's JYP0035 Receives Clinical Trial Approval for Breast ...
On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class 1 new drug, the PI3Kฮฑ inhibitor JYP0035 capsule, received clinical trial โฆSee details»
Guangzhou JOYO Pharma Co Ltd - PharmArch.com
June, 2023, Guangzhou JOYO Pharma Co., Ltd (JOYO PHARMA)announced that it has completed the pre-C round of financing of more than 100 million yuan. 2023-06-08. Hot โฆSee details»
Joyo Pharma's JYP0015 Receives CDE Approval for RAS Mutation โฆ
Feb 24, 2025 China's Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma's Category 1 drug JYP0015, a molecular glue product, for clinical studies in hematological and โฆSee details»
Chinese pharma firms Joyo, Zion secure Series B funding
Jul 28, 2021 Chinese pharma firms Joyo, Zion secure Series B funding. Photo: Getty Images Pro via DealStreetAsia. Liya Su. 28 July, 2021. Joyo Pharma has secured over 300 million yuan ($46 million) in its Series B round while โฆSee details»
Guangzhou JOYO Pharma Co., Ltd - Patsnap
Mar 12, 2023 Guangzhou JOYO Pharma Co., Ltd is headquartered in China Guangdong Sheng. Guangzhou JOYO Pharma Co., Ltd was founded in 2017. Guangzhou JOYO Pharma Co., Ltd โฆSee details»
Sufenidone - Guangzhou JOYO Pharma - AdisInsight - Springer
Nov 24, 2023 14 Jan 2023 Guangzhou JOYO Pharma completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in China (PO) ( NCT06135363) You need to be a logged in โฆSee details»
Joyo Pharma - Crunchbase
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.See details»
Series C - Joyo Pharma - 2023-06-07 - Crunchbase
Joyo Pharma raised $14025639 on 2023-06-07 in Series C. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Funding Round. Series C - Joyo โฆSee details»
JunHe Advises Joyo Pharmatech on its Licensing of Pan-RAS(ON) โฆ
Dec 25, 2024 On May 17, 2024, Joyo Pharmatech Co., Ltd. (โJoyoโ) and Erasca, Inc. (Nasdaq: ERAS) announced that they have entered into an exclusive worldwide license agreement for โฆSee details»
Erasca doubles down on RAS | ApexOnco - Clinical Trials news and โฆ
May 17, 2024 Remarkably, the Joyo deal is at least the eighth transaction Erasca has struck to bring in R&D assets since it was founded in 2018, but most have now fallen by the wayside. โฆSee details»
Sudapyridine (WX-081) | Working Group for New TB Drugs
WX-081 is under investigation in a phase 2 study in patients." And from the Shanghai Jiatan Biotech Ltd., a subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China the following โฆSee details»
Joyo Pharma - Updates, News, Events, Signals & Triggers
Joyo Pharma raised CN¥100,000,000 / Series C from Anxin Guosheng Microchip Fund and 2 other investors Discover more funding rounds Funding Round โข Jul 28, 2021See details»
Nonprofit Drug Companies: Information on Funding, Drug Types ...
May 1, 2025 What GAO Found. Nonprofit drug companies have more recently emerged as an alternative model to for-profit drug companies. While both bring brand-name and generic drugs โฆSee details»